ImmuneRegen BioSciences Inc announces IND submission for Homspera for the treatment of Idiopathic Pulmonary Fibrosis.

ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings Inc, is announcing the submission of an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) to begin human clinical testing of Homspera, an analog of the endogenous neurokinin Substance P. The company plans to evaluate Homspera initially as a treatment for Idiopathic Pulmonary Fibrosis, a condition for which there are no consistently effective drugs approved for human use in the US. Homspera is an …